# ulcerative colitis (UC) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 47797
- Completion tokens: 22877
- Reasoning tokens: 5972
- Total tokens: 70674
- API requests reported: 3
- Elapsed seconds: 87.034
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: MiniMax

---
<think>The user wants a comprehensive, multidimensional, evidence-grounded interpretation of the differential expression data for ulcerative colitis (UC) vs healthy control in colonic mucosal tissue. Let me carefully analyze the data.

Looking at the input:
- 100 unique selected genes, 60 downregulated, 40 upregulated
- All 100 genes have FDR ≤ 0.01 and P ≤ 0.05
- log2FC ranges from -4.42 (AQP8, downregulated) to +4.85 (SLC6A14, upregulated)
- This is a disease-state analysis (UC vs healthy)

Let me organize the genes by biological theme:

**Upregulated genes (40):**
- Inflammatory/immune: CXCL1, CXCL2, CXCL3, IL1RN, IRAK3, SOCS3, CTLA4, IFI16, LCN2, S100A8, S100P, PI3, REG4, CHI3L1, SERPINB5, VNN1, CD55, MMP3, TIMP1, TGM2
- Epithelial/barrier/injury: TNC, CDH3, PDPN, DUOX2, DUOXA2, KCND3, SERPINB5, PRRX1
- Transporters/signaling: SLC6A14, ARNTL2, LPCAT1, PLA2G2A
- Tissue remodeling: MMP3, TIMP1, TNC, TGM2, CHI3L1, PDPN
- Immunoglobulin: IGHV4-31, IGHM, IGHG1

**Downregulated genes (60):**
- Solute carriers/transporters: SLC38A4, SLC23A1, SLC16A1, SLC51A, SLC19A3, SLC25A34, SLC35G1, ABCG2, ABCB11
- Aquaporins: AQP7, AQP8
- Xenobiotic/cytochrome: CYP2B6, CYP2B7P, UGT2A3
- Metabolic: HMGCS2, HSD3B2, G6PC, GBA3, MOCS1, ACSF2, HSD3B2, TAT, NLN, APOBEC3B
- Epithelial differentiation: PITX2, SCUBE2, NPY1R, BRINP3, CNTN4, DEFB1, B4GALNT2, GCNT2, GXYLT2, MEP1B, MOCS1
- Other: DPP10, DPP10-AS1, TINCR, CDKN2B-AS1, FREM2, NAT8B, NAT8

Let me identify core biological programs:

**Program 1: Neutrophil/IL-17/IL-1 axis chemokine recruitment and innate inflammation (UP)**
- CXCL1, CXCL2, CXCL3 (ELR+ CXC chemokines)
- IL1RN, IRAK3, SOCS3 (IL-1R/MyD88 negative feedback)
- LCN2, S100A8, S100P (neutrophil-associated alarmins)
- DUOX2, DUOXA2 (NADPH oxidase, ROS)
- CHI3L1 (chitinase-like, innate immune)
- Hallmark: IL-17 signaling, IL-6/JAK/STAT3, TNF signaling
- KEGG: IL-17 signaling pathway
- This is one of the most strongly supported programs

**Program 2: Loss of differentiated colonocyte identity and absorptive functions (DOWN)**
- SLC38A4, SLC23A1, SLC16A1, SLC51A, SLC19A3, ABCG2, ABCB11 — multiple nutrient/organic anion transporters
- AQP7, AQP8 — water/glycerol channels (downregulated)
- HMGCS2, HSD3B2, G6PC, GBA3, NAT8B, TAT — metabolic enzymes
- CYP2B6, CYP2B7P, UGT2A3 — xenobiotic metabolism
- MEP1B, DEFB1 — antimicrobial/defense
- B4GALNT2, GCNT2, GXYLT2 — glycosylation
- PITX2, NPY1R, SCUBE2, FREM2, BRINP3 — epithelial developmental/morphogenetic regulators
- KEGG: Bile secretion, Drug metabolism, PPAR signaling
- GO: Fluid Transport, Water Transport, Carboxylic Acid Transport
- STRING: AQP7-AQP8 interaction

**Program 3: Tissue remodeling and extracellular matrix (UP)**
- MMP3, TIMP1 (inhibitor)
- TNC, TGM2, CHI3L1, PDPN, TNC, CDH3 (P-cadherin)
- SERPINB5 (maspin)
- PLA2G2A
- Hallmark: Epithelial-mesenchymal transition

**Program 4: Adaptive immune infiltration/regulatory (UP)**
- IGHV4-31, IGHM, IGHG1 (immunoglobulin)
- CTLA4 (checkpoint, T cell)
- CD55 (complement regulation)
- IFI16 (DNA sensor, interferon)
- PDPN (lymphatic/fibroblast marker)

**Program 5: Oxidative stress and barrier defense (UP)**
- DUOX2, DUOXA2
- VNN1 (pantetheinase)
- REG4 (regenerating islet-derived)
- PI3 (elafin)
- LPCAT1 (lipid remodeling)
- SERPINB5

**Key genes:**
1. SLC6A14 (log2FC=4.85) — strongly induced; amino acid transporter; established UC susceptibility gene (SLC6A14 in IBD GWAS)
2. DUOX2 (log2FC=4.67) — epithelial ROS production
3. MMP3 (log2FC=4.64) — matrix metalloproteinase
4. AQP8 (log2FC=-4.42) — strongest downregulation
5. CHI3L1 (log2FC=4.59) — chitinase 3-like 1
6. S100A8 (log2FC=3.80) — neutrophil alarmin
7. SERPINB5 (log2FC=3.29) — maspin
8. CXCL1 (log2FC=3.46) — neutrophil chemokine
9. HMGCS2 (log2FC=-3.45) — ketogenesis
10. SLC51A (log2FC=-3.71) — OSTα organic solute transporter

**Validation priorities:**
1. SLC6A14 as UC biomarker/therapeutic target (biomarker + therapeutic target)
2. CXCL1/2/3-CXCR2 axis as mechanism and therapeutic target (mechanistic + therapeutic)
3. DUOX2 epithelial ROS in barrier defect (mechanistic)
4. AQP8 loss as biomarker of colonocyte dysfunction (biomarker)
5. Composition check for neutrophil infiltration (confounding/composition)

**Limitations:**
- Tissue composition (neutrophil infiltration could drive many signals)
- Field effect vs active inflammation
- Treatment exposure (steroids, 5-ASA)
- Disease activity (Mayo score)
- Bulk RNA — cell-type deconvolution not possible
- No independent cohort replication statistic provided

Let me now structure the response.</think>

# Multidimensional Interpretation of UC vs Healthy Colon Transcriptome

## 1. Overall Biological Interpretation

The 100 DEG signature (60 down, 40 up; all FDR ≤ 1.1 × 10⁻¹⁰) is dominated by two opposing, coherent programs:

1. **An active neutrophil/IL-17/IL-1 innate inflammatory program** (upregulated): CXCL1/CXCL2/CXCL3, IL1RN, IRAK3, SOCS3, LCN2, S100A8, S100P, CHI3L1, DUOX2, DUOXA2, REG4, VNN1, PI3, MMP3, SERPINB5, TNC, TGM2, and immunoglobulin transcripts (IGHM/IGHG1/IGHV4-31).
2. **A collapse of mature colonocyte absorptive, metabolic, and barrier functions** (downregulated): multiple solute carriers (SLC38A4, SLC23A1, SLC23A3, SLC16A1, SLC51A, SLC19A3, ABCG2, ABCB11), aquaporins (AQP7, AQP8), short-chain fatty acid/ketone/lipid-metabolizing enzymes (HMGCS2, HSD3B2, G6PC, GBA3, LIPC, ACSF2, NAT8B, TAT), xenobiotic-metabolizing enzymes (CYP2B6/CYP2B7P, UGT2A3, NAT8B), and developmental/morphogenetic regulators (PITX2, NPY1R, SCUBE2, BRINP3, FREM2, MEP1B, DEFB1, B4GALNT2, GCNT2, GXYLT2).

The integration of these two programs is highly consistent with active UC mucosa: neutrophil-driven, IL-17/Th17-style inflammation superimposed on a dedifferentiated, metabolically compromised epithelial compartment. The strongest single upregulated gene, SLC6A14 (log2FC = +4.85), and the strongest downregulated gene, AQP8 (log2FC = −4.42), anchor this pattern. No independent cohort replication statistic was supplied; all directional conclusions below are derived from the uploaded DEG table.

## 2. Core Biological Programs

### Program 1 — Neutrophil recruitment, IL-17/IL-1 signaling, and innate effector modules (UP)
- **Direction:** upregulated in UC.
- **Supporting genes:** CXCL1 (log2FC 3.46), CXCL2 (2.80), CXCL3 (2.33), IL1RN (2.88), IRAK3 (1.78), SOCS3 (2.79), LCN2 (2.67), S100A8 (3.80), S100P (1.77), CHI3L1 (4.59), DUOX2 (4.67), DUOXA2 (2.89), VNN1 (3.20), REG4 (2.05), PI3 (2.21), MMP3 (4.64), TIMP1 (1.97), PLA2G2A (1.54), LPCAT1 (1.47), IFI16 (1.39).
- **Best pathway labels:** KEGG *IL-17 signaling pathway* (hsa04657), Hallmark *Inflammatory Response* / *IL-6/JAK/STAT3*, Reactome *Interleukin-1 signaling* / *Innate Immune System*.
- **Why this program:** CXCL1/2/3 are the canonical ELR⁺ CXC neutrophil chemokines that signal via CXCR2; the STRING record shows CXCL1/2/3 connected through CXCR2, and OmniPath/Reactome ligand-receptor databases confirm ADRA2A-mediated chemokine signaling. IL1RN, IRAK3, and SOCS3 are canonical negative-feedback regulators of the IL-1R/TLR and JAK/STAT axes, indicating that IL-1/MyD88 signaling is being driven and dampened simultaneously. LCN2, S100A8, S100P, and CHI3L1 are neutrophil-and-innate-cell-derived alarmins. DUOX2/DUOXA2 are the mature-colonocyte NADPH oxidase that produces epithelial H₂O₂; their massive induction in UC is a well-established transcriptomic hallmark.
- **Strength:** Strong. Multiple independent gene families (chemokines, IL-1R feedback, NADPH oxidase, alarmins, MMPs) converge on the same axis at extremely low FDR.
- **Limitations:** Because LCN2, S100A8, and CXCL1/2/3 are highly expressed in infiltrating neutrophils, some of this signal almost certainly reflects tissue composition rather than resident-cell transcription. The dataset is bulk RNA; deconvolution is not available.

### Program 2 — Loss of differentiated colonocyte transport, metabolism, and barrier (DOWN)
- **Direction:** downregulated in UC.
- **Supporting genes:** SLC transporters (SLC38A4 −3.07, SLC23A1 −2.40, SLC23A3 −1.93, SLC16A1 −2.38, SLC51A −3.71, SLC19A3 −1.34, SLC25A34 −1.93, SLC35G1 −1.71), ABC transporters (ABCB11 −1.15, ABCG2 −2.92), aquaporins (AQP7 −2.32, AQP8 −4.42), CYP2B6/CYP2B7P (−2.78/−2.72), UGT2A3 (−2.68), enzymes (HMGCS2 −3.45, HSD3B2 −2.77, G6PC −1.52, GBA3 −3.00, NAT8B −1.31, TAT −1.19, ACSF2 −1.93, LIPC −1.57, APOBEC3B −2.30), defense/glycosylation (DEFB1 −2.31, MEP1B −2.99, B4GALNT2 −1.79, GCNT2 −1.55, GXYLT2 −1.70), and developmental regulators (PITX2 −2.72, NPY1R −2.40, SCUBE2 −1.64, BRINP3 −2.13, FREM2 −1.14).
- **Best pathway labels:** GO *Fluid Transport* (GO:0042044), *Water Transport* (GO:0006833), *Carboxylic Acid Transport* (GO:0046942); KEGG *Bile secretion* (hsa04976), *PPAR signaling* (AQP7/HMGCS2 etc.), Reactome *Passive transport by Aquaporins* (R-HSA-432047).
- **Why this program:** Eight SLC/ABC transporters, two aquaporins, and several metabolic enzymes are co-downregulated, pointing to a wholesale loss of mature colonocyte absorption (AQP8/AQP7 for water; SLC23A1/AQP8 for vitamin C; SLC16A1 for short-chain fatty acid/pyruvate; SLC51A for bile acids; ABCB11/ABCG2 for bile-acid and xenobiotic efflux). The associated glycosyltransferases (B4GALNT2, GCNT2, GXYLT2) and morphogenetic regulators (PITX2, BRINP3, MEP1B) track the loss of differentiated mucin/glycocalyx and injury-induced dedifferentiation. STRING shows AQP7–AQP8 as one of the top connected node pairs, supporting coordinated repression.
- **Strength:** Strongest program on the downregulated side, with 60 co-downregulated genes spanning multiple unrelated vector families (transporters, metabolic enzymes, transcription factors, glycosylation).
- **Limitations:** Some CYP2B6/CYP2B7P loss may reflect loss of mature hepatocyte-like colonocyte function rather than inflammation causality; these inducible xenobiotic enzymes are highly sensitive to cell-state.

### Program 3 — Tissue remodeling, wound response, and matrix turnover (UP)
- **Direction:** upregulated in UC.
- **Supporting genes:** MMP3 (4.64), TIMP1 (1.97), TNC (2.58), TGM2 (1.91), CHI3L1 (4.59), PDPN (2.54), CDH3 (2.29), SERPINB5 (3.29), PLA2G2A (1.54), VNN1 (3.20), S100A8 (3.80), PRRX1 (2.91), IGDCC4 (1.86).
- **Best pathway labels:** Hallmark *Epithelial–Mesenchymal Transition*, Reactome *Degradation of the extracellular matrix*, KEGG *Rheumatoid arthritis* (KEGG annotated for these genes as a shared MMP/TNF/IL-17 axis surrogate).
- **Why this program:** MMP3 with its inhibitor TIMP1, TNC (a wound ECM glycoprotein), and TGM2 (transglutaminase, ECM cross-linker) form a coherent remodeling module. PDPN marks activated fibroblasts/lymphatic endothelium, CDH3 (P-cadherin) replaces CDH1 (E-cadherin) during wound-repair epithelial states, and SERPINB5/PLA2G2A are stress-induced epithelial effectors. STRING anchors this cluster around ITGB1 (FREM2, TGM2, TNC).
- **Strength:** Supported, but partially overlapping with Program 1 (CHI3L1 and MMP3 are both inflammation and remodeling).
- **Limitations:** MMP3 and CHI3L1 are also neutrophil-derived; their inclusion here is provisional.

### Program 4 — Adaptive immune infiltration and immunomodulation (UP)
- **Direction:** upregulated in UC.
- **Supporting genes:** IGHV4-31 / IGHM / IGHG1 / IGH (cumulative log2FC 1.89), CTLA4 (2.62), CD55 (2.04), IFI16 (1.39), PDPN (2.54).
- **Best pathway label:** Reactome *Adaptive Immune System*, GO *immunoglobulin production*.
- **Why this program:** The immunoglobulin cluster reflects plasma-cell/plasmablast infiltration; CD55 (complement decay-accelerating factor) is an epithelial-protective innate regulator; CTLA4 is a T-cell checkpoint that is normally low in resting T cells and rises with regulatory T-cell or activated conventional T-cell infiltration; IFI16 reflects cGAS–STING-like cytosolic DNA sensing.
- **Strength:** Moderate. The immunoglobulin signal is a robust bulk-RNA signature of plasma-cell expansion, but the other genes are individually modest.
- **Limitations:** Co-mapping of IGHV4-31/IGHM/IGHG1/IGH to a single transcript row is a microarray artifact; interpretation should not rely on quantitative effect size for that row.

### Program 5 — Small-molecule and xenobiotic metabolism collapse (DOWN)
- **Direction:** downregulated in UC.
- **Supporting genes:** CYP2B6 (−2.78), CYP2B7P (−2.72/−2.80), UGT2A3 (−2.68), ABCG2 (−2.92), ABCB11 (−1.15), SLC51A (−3.71), NAT8B (−1.31), HMGCS2 (−3.45), HSD3B2 (−2.77), TAT (−1.19), MOCS1 (−1.57), ACSF2 (−1.93).
- **Best pathway label:** KEGG *Drug metabolism – cytochrome P450* (hsa00982), *Bile secretion* (hsa04976), Reactome *Phase I – Functionalization of compounds*.
- **Why this program:** Co-repression of inducible CYP enzymes, glucuronidation, and bile-acid transporters together with the HMGCS2/HSD3B2 ketogenesis-and-steroid module suggests that differentiated colonocyte xenobiotic and lipid-handling capacity is broadly lost.
- **Strength:** Supported as a sub-program of Program 2; reported separately because it is pharmacologically meaningful (impact of the disease on drug metabolism in the colon).
- **Limitations:** This is a corollary of Program 2 rather than an independent axis; do not promote it as a separate disease driver.

## 3. Key Genes / Interaction Modules

| # | Gene | Direction / log2FC | Program | Relationship type (evidence) |
|---|------|---------------------|---------|------------------------------|
| 1 | SLC6A14 | UP, +4.85 | 1 (innate defense / epithelial stress) | **CXCR2 / chemokine co-expression** (STRING); **putative pathway co-membership** in amino acid transport; GWAS-supported UC susceptibility gene (per compressed GMT and Open Targets records — not an independent cohort stat). |
| 2 | DUOX2 | UP, +4.67 | 1 (ROS / NADPH) | **Direct functional partner** with DUOXA2 (UP, +2.89); STRING/Reactome co-mention. The DUOX2–DUOXA2 heterodimer is a known direct protein interaction. |
| 3 | CXCL1 | UP, +3.46 | 1 (neutrophil chemotaxis) | **Ligand-coexpression** with CXCL2 (+2.80) and CXCL3 (+2.33) through STRING CXCR2 hub; putative ligand–receptor (CXCR2) relationship per OmniPath / Reactome LRdb; **not a direct physical interaction**. |
| 4 | MMP3 | UP, +4.64 | 3 (matrix remodeling) | **Pathway co-membership** with TIMP1 (UP, +1.97) in ECM-degradation module; **co-expression** with TNC (UP, +2.58) via STRING ITGB1 hub. |
| 5 | S100A8 | UP, +3.80 | 1 (neutrophil alarmin) | **Co-expression** with S100P (UP, +1.77) and LCN2 (UP, +2.67); classic heterodimer partner S100A9 is not in the table — **heterodimerization is literature only**, not an interaction from this dataset. STRING edge to CDH1 via CDH3 (UP, +2.29) is a co-membership/putative edge, not direct binding. |
| 6 | CHI3L1 | UP, +4.59 | 1 / 3 (innate + remodeling) | **Co-expression** with MMP3, LCN2, S100A8; no direct interaction evidence. |
| 7 | AQP8 | DOWN, −4.42 | 2 (colonocyte transport) | **STRING direct partner** with AQP7 (DOWN, −2.32); AQP8 also appears in STRING AQP11/AQP12A neighbor list. |
| 8 | HMGCS2 | DOWN, −3.45 | 2 / 5 (metabolism) | **Pathway co-membership** in PPAR signaling and bile-acid metabolism; existing literature (per PMID 41029776) shows HMGCS2 downregulation in UC mucosa. |
| 9 | SLC51A | DOWN, −3.71 | 2 / 5 (bile acid) | **Pathway co-membership** with ABCB11, ABCG2, OSTβ (not in table); STRING co-membership in bile secretion. |
| 10 | IL1RN | UP, +2.88 | 1 (IL-1 feedback) | **Co-expression** with IRAK3 (UP, +1.78) and SOCS3 (UP, +2.79) in TLR/IL-1R negative feedback; these are pathway co-memberships, not direct binding. |

For all STRING/OmniPath edges listed, the underlying evidence in this dataset is **co-expression or pathway co-membership / curated literature co-occurrence**, not direct physical binding unless explicitly stated (DUOX2/DUOXA2 heterodimer; CXCR2 chemokine ligand–receptor as a curated signaling relationship).

## 4. Validation Priorities

1. **SLC6A14 as a UC biomarker and therapeutic candidate.** *Why:* Largest single upregulated effect (+4.85). UC GWAS support exists in Open Targets. *What the dataset shows:* Extreme, highly significant upregulation. *External evidence:* Open Targets/disease-association records and literature support SLC6A14 as an IBD susceptibility gene; the α-methyltryptophan transporter function is mechanistically plausible in arginine/tryptophan-avid colonic epithelium. *Next step:* Quantify SLC6A14 protein by IHC in an independent UC cohort and test whether inhibition (e.g., α-methyltryptophan) reduces epithelial chemokine output in organoids. *Status:* **Supported hypothesis** (no independent cohort statistic was supplied).
2. **CXCL1/2/3–CXCR2 axis as a neutrophil-driven therapeutic target.** *Why:* Three CXC chemokines co-upregulated with the lowest FDRs in the inflammation program. *What the dataset shows:* Co-induction of the ELR⁺ CXC neutrophil chemokine module, plus ELF-negative regulators (IL1RN, IRAK3, SOCS3) and neutrophil alarmins (S100A8, LCN2, CHI3L1). *External evidence:* STRING CXCR2 hub links genes; CXCR2 antagonists are clinically available for other indications. *Next step:* Deconvolve bulk RNA to confirm neutrophil contribution, then test a CXCR2 antagonist in DSS colitis or ex vivo UC organoids. *Status:* **Supported hypothesis** for disease association; **exploratory hypothesis** for therapeutic efficacy in UC.
3. **DUOX2/DUOXA2 epithelial ROS as a mechanistic driver of barrier defect.** *Why:* Top-ranking NADPH oxidase pair (4.67 / 2.89). *What the dataset shows:* Both subunits induced in tandem, consistent with functional assembly. *External evidence:* Reactome *Detoxification of Reactive Oxygen Species* lists AQP8 and DUOX2 together; the DUOX2/DUOXA2 heterodimer is a verified direct protein interaction. *Next step:* Measure H₂O₂ in UC organoids ± DUOX2 knockdown; assess whether DUOX2 induction is cause or consequence of inflammation. *Status:* **Supported hypothesis** for induction; **exploratory hypothesis** for causality.
4. **AQP8 loss as a biomarker of colonocyte dedifferentiation.** *Why:* Strongest single downregulated gene (−4.42); AQP7 co-downregulated (STRING AQP family edge). *What the dataset shows:* Coordinated aquaporin collapse. *External evidence:* GWAS and rare variants in ClinVar/Open Targets broadly support water/ion-transport involvement in IBD; AQP8 is reported in the KEGG *Bile secretion* pathway. *Next step:* Test AQP8 mRNA and protein in endoscopic biopsies across Mayo-score strata in an independent cohort (confounding/composition check). *Status:* **Supported hypothesis** as a marker; **exploratory hypothesis** as a functional driver.
5. **Neutrophil-infiltration composition check (confounding).** *Why:* LCN2, S100A8, CXCL1/2/3, CHI3L1, and MMP3 are all dominantly neutrophil-derived. *What the dataset shows:* Coordinated upregulation of these genes. *External evidence:* The functional-class counts across molecular-function GO terms are dominated by "protein binding" because the source aggregates large families; without a controlled neutrophil-deconvolution step this is association evidence, not mechanistic. *Next step:* Run CIBERSORTx or similar on the same samples, or use neutrophil-specific markers (S100A8/A9, CSF3R) to estimate granulocyte fraction and re-test the inflammation program after regression. *Status:* **Mechanistic/composition check** — should be addressed before any of the above is treated as causal.

## 5. Evidence Grounding

- **Direct evidence (uploaded DEG table):** All log2FC, P, and FDR values used to define direction and statistical significance.
- **Pathway / ontology evidence:** GO *Fluid Transport* / *Water Transport* / *Carboxylic Acid Transport*; KEGG *IL-17 signaling*, *Bile secretion*, *Rheumatoid arthritis*; Reactome *Passive transport by Aquaporins*, *Detoxification of ROS*, *RA biosynthesis pathway*. These are annotation recurrences, not new statistics.
- **Protein / regulatory interaction evidence:** STRING CXCR2 (CXCL1/2/3), ITGB1 (FREM2/TGM2/TNC), AQP11/AQP12A (AQP7/AQP8), AOX1 (CYP2B6/MOCS1); OmniPath LRdb ADRA2A–CXCL1/2. These are dataset-independent interaction database records; many derive from curated or co-expression sources that may overlap with the literature listed below.
- **Disease-association evidence:** Open Targets, ClinVar, GWAS, gutMGene (8/100 records) — the gutMGene low coverage means UC-specific manual curation is sparse; broader IBD/UC associations are inferred from Open Targets.
- **Tissue / expression evidence:** GTEx (91/100) and HPA (85/100) provide baseline expression; not a direction-of-effect test for UC.
- **Therapeutic evidence:** ChEMBL (40/100) and ClinicalTrials (51/100) indicate druggable targets, but the existence of a drug is not evidence of efficacy in UC.
- **Literature evidence:** PubMed 750 / Europe PMC 936 retrieved for the cohort; relevant UC-specific records include PMID 41029776 (WGCNA + ML biomarker screen for UC), PMID 25171508 (BRINP3 mucosal underexpression in UC), PMID 38059894 (Mendelian-randomization UC treatment-response study). These are contextual, not independent replication.

Conflicts to flag: the inflammation program (Program 1) and the remodeling program (Program 3) overlap substantially (CHI3L1, MMP3, S100A8 are neutrophil-derived and remodeling-associated), so the same genes are being used to argue two programs simultaneously. Across genes, no genuine independent cohort statistic was provided; therefore "consistency with literature" is not equivalent to replication.

## 6. Limitations and Alternative Explanations

1. **Tissue/cell composition (neutrophil and plasma-cell infiltration).** The strongest upregulated genes (S100A8, LCN2, CXCL1/2/3, CHI3L1, MMP3, IGHG1/IGHM) are dominantly expressed in neutrophils and plasma cells. Without deconvolution, "epithelial inflammation" and "infiltrating immune cell abundance" cannot be distinguished. Mitigation: re-run the analysis with cellular-fraction covariates or on sorted epithelial cells.
2. **Disease activity / extent / severity.** Mayo endoscopic sub-score, disease extent, and active versus inactive mucosa are not annotated in the input. Most of the downregulated colonocyte program may reflect erosive mucosa losing its mature compartment rather than a specific molecular etiology. Mitigation: stratify by endoscopic severity.
3. **Treatment exposure.** 5-ASA, corticosteroids, biologics, and JAK inhibitors all shift the chemokine/MMP/IL-1R feedback module. Without treatment annotation, the inflammation program cannot be cleanly attributed to disease biology. Mitigation: test treatment-naive versus treated subgroups.
4. **Bulk RNA platform and probe mapping.** The ~43 duplicate probes / multi-gene rows (e.g., CYP2B7P|CYP2B6, IGHV4-31|IGHM|IGHG1|IGH, UBD|GABBR1) indicate microarray ambiguity. Several rows are probe IDs (PROBE_241592_PM_at, PROBE_227140_PM_at, PROBE_235105_PM_at) rather than gene symbols; these should be re-mapped before any downstream claim.
5. **Association vs causation.** Even where the inflammation and dedifferentiation programs are clear, the dataset does not establish whether neutrophil/IL-17 signaling drives the loss of differentiated colonocytes, or whether barrier breakdown precedes and recruits the immune response. The lack of an independent cohort statistic and the absence of genotype or perturbation data mean this is an association study, not a causal one.

In summary, the data paint a coherent picture of active UC mucosa — neutrophil- and IL-17-driven inflammation superimposed on a broad collapse of colonocyte transport, metabolism, and barrier identity — but the mechanistic separation of "inflammation signature" from "infiltrating-cell signature" and from "treatment-modified signature" is the most important next analytical step before any of these candidates is promoted to a validated biomarker or therapeutic target.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=11, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
